Law Commons^™

Unregulable Defenses And The Perils Of Shareholder Choice, Jennifer Arlen, Eric L. Talley

Faculty Scholarship

A significant debate rages within corporate law scholarship as to whether shareholders or managers should be granted authority over the tender offer process once a bid is imminent. Both sides generally agree that the issue depends on whether shareholders are capable of exercising informed choice over takeover bids. Supporters of managerial veto power contend that the arguments favoring professional management of publicly held firms carry over into the tender offer context. Proponents of shareholder choice, on the other hand, argue that shareholders can act on their own behalf in the special circumstances surrounding contests for corporate control.

This Article challenges …

Poison Pills And The European Case, Jeffrey N. Gordon

Faculty Scholarship

Professor Coates has given us a welcome opportunity to revisit the question of shareholder rights plans, or poison pills. It is interesting to evaluate a revisionist's view of an important empirical debate – but less because of the role that empirical evidence may have played in the evolution of U.S. corporate law doctrine and more because of the relevance of that debate to a world, especially Europe, that is waking up to the vigorous market in corporate control. If contested takeovers involving target firms such as Gucci, Telecom Italia, Paribas, and Mannesman are headline grabbing events in 1999 and 2000, …

"Just Say Never?" Poison Pills, Deadhand Pills, And Shareholder-Adopted Bylaws: An Essay For Warren Buffett, Jeffrey N. Gordon

Faculty Scholarship

My topic is Buffett on mergers and acquisitions and how his sage advice on the importance of shareholder choice should be taken to heart by the Delaware Supreme Court, which will soon face far-reaching questions on the distribution of power between shareholders and the board of directors. Recent judicial decisions in other jurisdictions: (i) have declared that a board can maintain a poison pill in the face of a premium hostile bid, the power to "just say no;" (ii) have validated the board's adoption of a so-called "deadhand pill," a poison pill that can be redeemed only by continuing directors; …